Showing results (21-30 of 36) with videos related to

Sort By:
Pageof 4
European Journal of Medical Research|July 6, 2006
Pharmacokinetics and tolerability of a combination of indinavir, lopinavir and ritonavir in multiply pretreated HIV-1 infected adultsNils von Hentig, A Müller, C Rottmann, et al.
HIV/AIDS (Auckland, N.Z.)|August 16, 2021
Evaluation of Platelet Activation by HIV Protease Inhibitors - The HIV-PLA II StudyGerrit Kann, Junaid Owasil, Karina Kuczka, et al.
Pharmacogenetics and Genomics|June 11, 2009
Cross-sectional analysis of the influence of currently known pharmacogenetic modulators on opioid therapy in outpatient pain centersJörn Lötsch, Nils von Hentig, Rainer Freynhagen, et al.
European Journal of Clinical Pharmacology|December 25, 2009
Atazanavir plasma concentrations are impaired in HIV-1-infected adults simultaneously taking a methadone oral solution in a once-daily observed therapy settingAnnette Haberl, Manfred Moesch, Gabriele Nisius, et al.
Thrombosis and Haemostasis|June 4, 2004
Transition from argatroban to oral anticoagulation with phenprocoumon or acenocoumarol: effects on prothrombin time, activated partial thromboplastin time, and Ecarin Clotting TimeSebastian Harder, Jochen Graff, Ute Klinkhardt, et al.
The Journal of Antimicrobial Chemotherapy|August 30, 2008
Platelet-leucocyte adhesion markers before and after the initiation of antiretroviral therapy with HIV protease inhibitorsNils von Hentig, Ann-Kristin Förster, Karina Kuczka, et al.
AIDS (London, England)|April 20, 2004
Saquinavir drug exposure is not impaired by the boosted double protease inhibitor combination of lopinavir/ritonavirChristoph Stephan, Nils von Hentig, Irene Kourbeti, et al.
Antiviral Therapy|February 7, 2009
Pharmacokinetics, safety and efficacy of saquinavir/ ritonavir 1,000/100 mg twice daily as HIV type-1 therapy and transmission prophylaxis in pregnancyNils von Hentig, Gabi Nisius, Tessa Lennemann, et al.
Antimicrobial Agents and Chemotherapy|March 23, 2011
Sequential population pharmacokinetic modeling of lopinavir and ritonavir in healthy volunteers and assessment of different dosing strategiesLaura Dickinson, Marta Boffito, David Back, et al.
Therapeutic Drug Monitoring|March 18, 2014
Lopinavir/ritonavir pharmacokinetics, efficacy, and safety in HIV and hepatitis B or C coinfected adults without symptoms of hepatic impairmentPavel Khaykin, Peter Kotzerke, Christoph Stephan, et al.
Pageof 4